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Abstract
Response to a drug often differs widely among individual patients. This variability is frequently 
observed not only with respect to effective responses but also with adverse drug reactions. 
Matching patients to the drugs that are most likely to be effective and least likely to cause harm is 
the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision 
medicine through elucidating the genetic determinants responsible for pharmacological outcomes 
and using them to guide drug selection and dosing. Here, we survey the US landscape of research 
programs in PGx implementation, review current advances and clinical applications of PGx, 
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summarize the obstacles that have hindered PGx implementation, and identify the critical 
knowledge gaps and possible studies needed to help to address them.
Introduction
Patients’ responses to pharmacological treatments are highly variable, ranging from effective 
treatments to fatal adverse drug reactions (ADRs). Some of this variation is attributable to 
inherited genetic differences, and many genomic variants influencing responses to frequently 
used drugs have been identified (1). Pharmacogenomics (PGx) is the science of identifying 
and validating genomic variants influencing drug response and implementing strategies to 
use such genomic information to inform treatment decisions. It has become one of the 
leading and potentially most actionable areas of precision medicine.
Translating PGx discoveries into clinical care remains a challenge for a number of reasons, 
including limited evidence that implementing PGx-guided drug therapy improves patient 
outcomes. Several projects initiated by academic medical centers and hospital systems have 
approached PGx-implementation projects as quality-improvement initiatives, demonstrating 
the high frequency of pharmacogenetically-relevant genomic variants and the potential value 
of PGx-guided drug selection (2–4). Such patient-safety programs provide a useful pathway 
for moving PGx information into clinical practice, but the role of further research efforts to 
inform this translation remains poorly defined.
Research into the functional effects of PGx variants and their relationships to drug response 
has been conducted for decades (1), while PGx-implementation research focusing on 
adoption or uptake of clinical interventions by providers and/or healthcare systems is in a 
relatively early stage. Here, we survey the US landscape of research programs in PGx 
implementation, review current advances and clinical applications of PGx, summarize the 
obstacles that have hindered PGx implementation, and provide recommendations for moving 
forward. These areas were highlighted in a May 2017 symposium convened by the National 
Human Genome Research Institute (NHGRI) (5) that was attended by ~40 clinicians and 
PGx researchers.
Illustrative Examples of Resources of Value for PGx Implementation
Several resources are available to support PGx discoveries and clinical implementation, such 
as the Pharmacogenomics Knowledgebase (PharmGKB), its affiliated Clinical 
Pharmacogenetics Implementation Consortium (CPIC), and Supporting Practice through 
Application, Resources, and Knowledge (SPARK) toolbox of the Implementing Genomics 
in Practice (IGNITE) network (Table 1). PharmGKB, CPIC, and other resources are expertly 
curated and annotated, providing valuable information on gene-drug associations important 
for clinical care. The Pharmacogenomics Clinical Annotation Tool (PharmCAT), the 
Displaying and Integrating Genetic Information Through the EHR (DIGITizE) program, and 
the Clinical Decision Support KnowledgeBase (CDS-KB) provide open-source tools and 
guides for clinical annotation of PGx-relevant genomic variants and clinical decision support 
(CDS) models for use in clinical care.
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The symposium participants and investigators from other known PGx implementation 
projects provided information on the use of these resources and other aspects of the PGx-
implementation landscape (Table 2). The goal was to collect information for each major 
clinical PGx-implementation project via a survey. Recipients of the survey were identified as 
the Principal Investigators of major genomic implementation projects such as the IGNITE, 
Clinical Sequencing Evidence-Generating Research (CSER), electronic Medical Records 
and Genomic (eMERGE) consortium and sites implementing the CPIC guidelines [https://
cpicpgx.org/implementation/]. In total, information on 40 projects was obtained from 36 
participants, with some reporting on more than one project. The survey yielded a 49% 
response rate (36 of 73 invited). In 57% of the projects, PGx was implemented in both 
clinical and research environments; in 28%, it was implemented in clinical environments 
only. Respondents reported conducting projects in the following research settings: 53% 
reported that it was conducted in an academic institution, 22% in a non-academic setting, 
14% in a hospital, and 11% in other healthcare settings. Roughly one-third of projects were 
implementing reactive PGx testing, in response to treatment plans, and the remainder 
implementing preemptive testing involving genotyping and/or DNA sequencing. CDS 
strategies prompting PGx testing orders or notification of PGx test results included both 
active (information and online ordering algorithms automatically presented to the clinician) 
and passive (information available to clinicians if sought and opened online) approaches for 
most projects. Submitting claims for third-party reimbursement for PGx testing was quite 
common, with 60% of projects having submitted in the past, submitting currently, or 
planning to do so in the future. Nearly all respondents used CPIC as a resource, followed by 
PharmGKB, IGNITE SPARK, and ClinVar. There was diversity in the genotyping platforms 
used by the projects, including Real-Time PCR Systems to characterize “Absorption, 
Distribution, Metabolism, and Excretion” genes (ADME; e.g., Sequenom iPLEX® ADME 
pharmacogenetic Panel and Illumina VeraCode® ADME Core Panel) and “Drug 
Metabolism Enzymes and Transporters” (DMET; Affymetrix DMET™ Plus) gene panels. 
The most common PGx gene-drug pair tested in the projects surveyed was CYP2C19-
clopidogrel, followed by SLCO1B1-simvastatin, CYP2C9/VKORC1-warfarin, and TPMT-
thiopurines. Reported obstacles included lack of a sustainable business plan; poor test 
reimbursement; lack of institutional support; challenges integrating with the electronic 
health records (EHR) ecosystem (such as EHR vendor changes by healthcare systems, lack 
of EHR infrastructure to support CDS alerts, and widespread use of PDF-based reporting 
that is often poorly suited for CDS integration); challenges in genotyping technology 
(including lengthy turn-around time for test results and the need to update panels as new 
testing information becomes available); need for education of clinical staff and patients; and 
lack of clinician acceptance.
Factors Affecting PGx Implementation and Illustrative Research Projects
Stakeholder Alignment and Transdisciplinary Teams
Key elements for healthcare systems to successfully adopt and sustain evidence-based PGx 
testing include the alignment of clinical and administrative stakeholders (e.g., senior 
administrative and clinical leadership, pharmacy and therapeutics committee members, 
laboratory directors, health information technology leaders, patients and patient advocates, 
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and third-party payers). The power of advocacy groups and social media to promote PGx-
research initiatives is exemplified by the Metastatic Breast Cancer Project “Count Me In,” in 
which patient self-registration has been far more effective than relying upon physician 
referrals (6). Alignment of common interests and concerns within and across these groups, 
especially aligning education and dissemination with new guidelines and reports in the 
popular press, is essential for adopting a given PGx initiative into routine clinical care. An 
example of this approach is represented by The INdiana GENomics Implementation 
Opportunity for the UnderServed (INGENIOUS) project, which studies the effect of 
prospective and reactive PGx genotyping on healthcare costs and ADR (7).
Availability of PGx genetic testing
Another factor is the availability of rapid, reliable, and low-cost PGx testing in a clinical 
environment. Implementation projects such as the African American Cardiovascular PGx 
CONsorTium (ACCOuNT) and the Genomic Prescribing System at Northwestern University 
(8) successfully use pre-emptive testing to provide PGx information to the clinician at the 
point of prescribing. Pre-emptive testing of patients likely to receive a drug with established 
PGx guidance obviates the need for rapid turnaround time but requires that the PGx test 
results and PGx guidance be readily available once the drug is actually ordered. The 
fragmentation of healthcare delivery in the US hinders the successful storage, portability, 
and actionability of such preemptive tests on a scalable basis.
Clinical tools for genomic implementation of PGx variants
Implementation tools and workflows to allow clinicians to order and act upon PGx tests are 
also important for PGx implementation. The six-hospital Mission Health System has 
developed system-wide CDS alerts to efficiently implement their test ordering. Vanderbilt 
University Medical Center also uses CDS linked to EHR as a quality-improvement initiative 
to show the impact of PGx-guided prescribing on patient care. Vanderbilt’s PGx Resource 
for Enhanced Decisions In Care and Treatment (PREDICT) program began with a specific 
implementation effort of CYP2C19-testing prior to clopidogrel use (4) and later expanded to 
include several other genes and drugs. The PREDICT program highlighted the variability in 
implementation among providers, and noted that provider acceptance depended on their 
belief in clinical efficacy, familiarity with alternatives, and perceptions about the ease of 
implementation (9). Acceptance was maximized by presenting test results that were easy to 
understand and that included recommendations based on clinically validated guidelines. 
Appropriate alternative medication use was maximized by having PGx results available at 
the time of initial prescribing.
Workforce Education
An educated multidisciplinary workforce (including physicians, pharmacists, nurses, and 
others interacting with patients and their medications) is another important component for 
effective PGx implementation. Healthcare providers must clearly understand what PGx 
testing is available, whether the results are available preemptively (and, if not, when and how 
to order them), and what to do in the event of receiving an actionable result or “clinical 
alert.” The IGNITE University of Florida (UF) Personalized Medicine Program has 
observed a lack of appropriate training and clinical experience with PGx in both pharmacy 
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and medical schools (personal communication, J. Johnson). To test the effects of active 
learning and personal genotyping on student knowledge, a control group of students was 
enrolled in a required PGx course, and another group (the intervention group) enrolled in the 
required PGx course as well as an elective clinical PGx course and had the option to undergo 
their own panel-based genotyping and to use PGx data in working through case examples. 
Post-course knowledge test scores from the intervention group were higher than the control 
group, suggesting that confidence and knowledge needs to go hand-in-hand. Their study 
showed that post-course knowledge test scores are higher when knowledge and practical 
applications are given at the same time and that in general when more instruction on a topic 
is given students tend to receive better test scores (unpublished data) (10).
Cost-effectiveness of PGx implementation
Demonstration of PGx cost-effectiveness would facilitate acceptance and implementation by 
hospital systems and payers. The eMERGE-PGx Project implemented a PGx-sequencing 
panel at multiple sites (11), and explored diverse approaches to designing and implementing 
PGx-based CDS alerts and collecting outcomes. Although no cost-effectiveness analyses 
were conducted in this preliminary effort, the collection of clinic/facility-level economic 
outcomes and expanded development of well-validated instruments to assess implementation 
outcomes particularly relevant to PGx should be considered in the future. In the meantime, 
the sites are collaborating to report descriptive metadata and define quantitative and 
qualitative outcomes across many domains pertinent to cost-effectiveness analyses.
In addition to prospective data collection, cost-effectiveness can be estimated using 
economic modeling. An example from Geisinger Health System examined the use of IL28B 
genotyping to inform the use of triple therapy for Hepatitis C viral genotypes 2 and 3 (12). 
Threshold analysis predicted a high likelihood of cost-effectiveness if IL28B genotyping 
results were routinely used; this was subsequently implemented clinically. More extensive 
economic analyses for pharmacogenomics is underway at Vanderbilt (unpublished data) (13, 
14).
Clinical effectiveness of PGx implementation
Finally, it is clear that new approaches for demonstrating the clinical effectiveness of PGx 
implementation would be helpful. It is not feasible to generate randomized clinical trial 
evidence to test the benefits of PGx-guided prescribing for every gene-drug pair in every 
population (15). Members of the IGNITE Network utilized a pragmatic study design (16) to 
examine outcomes with CYP2C19 genotype-guided antiplatelet therapy in patients 
undergoing percutaneous coronary intervention; this was performed while awaiting the 
results of an ongoing traditional randomized clinical trial with an estimated completion date 
of 2020 (17). Each of the 7 participating sites had implemented CYP2C19-variant testing in 
clinical practice and recommended alternative antiplatelet therapy over clopidogrel for 
patients with a non-functional CYP2C19 allele indicative of reduced clopidogrel 
effectiveness. The team reviewed medical records for genotyped patients to identify major 
adverse cardiovascular events in the year following percutaneous coronary intervention. 
Fewer events occurred when genotype results were available early after coronary 
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intervention and alternative therapy was prescribed in patients with a non-functional 
CYP2C19 allele (18).
Population Diversity
Inadequate characterization of PGx-relevant genomic variants across persons of diverse 
ancestry, while largely a gap in discovery and validation of PGx-relevant variants, also 
contributes to major gaps in PGx implementation. Addressing this problem is critical for 
ensuring that all groups benefit from PGx implementation (19). Several minority patient-
engagement groups have been involved in advocating for additional minority-centered PGx 
initiatives. In addition, data for implementing PGx in pediatrics are modest, and 
extrapolating adult PGx data to children has some limitations (20). To address this disparity 
in pediatric PGx knowledge, Kansas City’s Children’s Mercy Hospital created the 
GOLDILOKs (Genomic and Ontogeny-Linked Dose Individualization and cLinical 
Optimization for Kids) Initiative (21), which includes stage of physical development in 
addition to genomic variation as a key determinant of drug selection and dosing. Providers 
focus on educating children and families about how dosing might differ; this has produced 
creative explanatory material (22) that are more understandable to children.
Lessons Learned
Stakeholder Alignment and Transdisciplinary Teams
Implementation research requires transdisciplinary teams that include expertise in genomics, 
clinical engineering, informatics, health services research, economics, and organizational 
science, as well as operational partners including administrators, clinicians, HIT 
professionals, payers, and patients. The adoption of PGx, as with many aspects of genomic 
medicine implementation, is often best advanced by identifying a local “clinical champion”; 
such an individual can help develop clinically relevant knowledge that can be widely applied 
beyond the individual system under study and encourage (and set an example for) other 
providers (23). The role of pharmacists as clinical champions deserves more study, given 
that several of the most successful clinical PGx programs are led by senior pharmacists and 
pharmacologists.
Availability of PGx genetic testing
Implementation of PGx testing is rarely cost-effective when performed in a ‘one gene at a 
time’ fashion (24, 25) because such testing only benefits the small portion of the population 
that both receives the particular drug and carries a variant associated with a super-, non-, or 
adverse response. Detecting meaningful differences in clinical outcomes with PGx testing 
for a single gene-drug pair is inefficient compared to multi-gene testing because the latter is 
relatively inexpensive and because more than 90%of the population carries high-risk alleles 
for multiple pharmacologically relevant genes (“pharmacogenes”)(8) and many will be 
prescribed multiple pharmacogenetically actionable drugs in their lifetimes (26). A more 
genomic approach, assessing most or all known drug-gene interactions via well-designed 
PGx panel testing, is more likely to assess fully the impact of a broader implementation that 
would involve multiple drugs. Such an approach is currently being used in the European 
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Ubiquitous Pharmacogenetics (U-PGx) trial (27) as well as at Vanderbilt University (13, 14) 
and Mission Health (28) and others (8).
Clinical tools for Genomic Implementation of PGx Variants
Successful implementation also depends on integration of structured PGx test results and 
electronic CDS delivered through EHR ecosystems, which is complicated by the rapid 
evolution, incompatibility, and heterogeneity in both reporting laboratory and clinical EHRs. 
Competition for informatics resources can be intense when basic clinical care needs must 
take priority, and providing dedicated funding for PGx health information technology (HIT) 
support can help reduce this bottleneck. Rather than customizing “one-off” solutions for 
each system, more “off-the-shelf,” transportable solutions [similar to the plug-in application 
program interfaces (APIs) available for drug-drug interactions] would provide more options 
for EHR integration of PGx information. Implementation would also be facilitated by 
establishing laboratory-to-provider and provider-to-provider interfaces to automate transfer 
of standardized, structured PGx test results. CPIC has led a modified-Delphi process to 
develop standardized terms for PGx results that is being adopted for clinical use (29). Rapid 
transfer of structured data would enable the development and dissemination of CDS to 
translate and integrate genomic information into existing clinical workflows, allowing 
clinicians to make PGx-informed decisions at the point of care.
Workforce Education and Patient Engagement
Detailed advice to clinicians on making PGx-informed decisions needs to include education 
as a key component, especially for those serving high-risk populations. The potential for 
inappropriate action on PGx results by clinicians is well illustrated by the mistaken 
prescribing of high-risk drugs as alternatives to carbamazepine in the Hong Kong experience 
of HLA-B*15:02 testing (30), which resulted in fewer ADEs to carbamazepine but more 
ADEs to the alternatively prescribed drugs (e.g., phenytoin). System-wide training programs 
are needed at multiple levels and for multiple health professions; incorporation in medical/
pharmacy school curricula is an important step, but by itself will take decades to permeate 
care, so is not a tenable approach on its own. Separate certificate programs, stand-alone 
courses, online courses, and webinars, where discussion and interaction around relevant PGx 
cases are facilitated, all have roles to play. Examples of such courses include the UF’s 
Precision Medicine Conference (31) and the City of Hope’s Intensive Course in Cancer Risk 
Assessment (32), both of which could be replicated and disseminated nationwide. However, 
while necessary, these traditional approaches to education are not sufficient to enable 
appropriate use of PGx information. In particular, information available at the point of care 
and “just in time” to support clinician decision-making is also necessary (33).
Cost-effectiveness of PGx implementation, Reimbursement and Insurance Coverage
One barrier to payer engagement and reimbursement is the lack of useful CPT (Current 
Procedural Terminology) codes for genetic/genomic tests. There are currently over 50,000 
such tests in the Genetic Testing Registry GTR, including 45 for PGx, (34) but there are only 
about 200 CPT codes for these tests, (35) making it challenging for payers to know what is 
being ordered. Imprecision in coding not only produces a bottleneck in moving 
reimbursement forward, but can hinder research on the use and outcomes of specific PGx 
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tests. Despite several coordinated efforts to develop CPT codes for such tests, progress has 
been very slow. Some have argued that more generalized codes are needed, that could be 
applied to panels of pharmacogenetic tests (36). Improved coding may also facilitate 
generation of health economics data needed to support reimbursement for PGx.
PGx variant interpretation and Common Data Models/Measures
The success of the clinical use of PGx tests depends heavily on the accuracy and consistency 
of genomic-variant interpretation. Significant improvement in that interpretation has been 
demonstrated by data sharing and consensus approaches to adjudication of variants’ 
pathogenicity (37). Sharing of multiple laboratories’ interpretations in ClinVar and 
PharmGKB has provided transparency and permits accumulation of experience to resolve 
conflicting classifications that arise during community curation. To improve data quality, 
some payers are now requiring testing laboratories to submit their data to ClinVar as a 
condition for reimbursement (38). Peer-reviewed, curated, and documented assignments of 
function to PGx-relevant variants is part of CPIC guidelines, and will facilitate efforts of 
DIGITizE and other groups to standardize PGx-test results.
It would be helpful to use a common data model to facilitate data sharing, such as that 
developed by the Observational Medical Outcomes Partnership (OMOP) (39). Standardized 
outcomes, such as those being developed in IGNITE, CSER, and eMERGE, are also 
essential (40). This highlights the need for defining key outcomes at the outset and 
incorporating them in the study design. Engaging physicians, patients, and payers to develop 
those designs, select outcomes, conduct research, and disseminate results is critical to 
producing evidence that will be relevant to stakeholders. While standardization of data and 
outcomes is important, local factors (e.g., population, clinician workflow, and resources) 
must be considered if implementation is to be successful. Collection of data on 
dissemination and implementation from early sites of adoption using validated frameworks 
[e.g., Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) (41)] is 
essential to lowering the barriers to implementation in settings with fewer resources.
Recommendations for Implementation and Research
Standards to Guide PGx Implementation
Steps to promote PGx implementation include improving PGx testing by reducing 
turnaround time, increasing the user-friendliness of PGx reports, standardizing PGx test 
reports, and sharing interpretations of PGx-relevant genomic variants across clinical 
laboratories for open peer review via deposition in ClinVar and PharmGkB (along with 
supporting observations). High standards for PGx testing should be established by the 
scientific community, such as establishing a minimum set of genomic variants to be tested 
(42) in each pharmacogene and the minimum DNA-sequencing quality metrics to be 
achieved. Efforts to promote standard terminology for alleles and drug response phenotypes 
(such as poor-, extensive- or ultra-metabolizer) (29) represent an opportunity where a 
consensus can be reached and uniform terms among PGx experts can be adopted.
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Development of PGx guidelines by CPIC and other authoritative sources is critical for PGx 
implementation. Improving standardization and updating CDS programs using tools 
produced by CPIC and other resources such as CDS-KB, ClinGen, IGNITE, and DIGITizE 
would also promote implementation, and avoid each adopting site needing to interpret and 
implement guideline content individually into proprietary EHR systems. Rapidly evolving 
knowledge requires that systems are in place to facilitate updating of variant interpretations 
and guidelines for their use.
Steps to fill critical data gaps through research include experimenting with diverse 
approaches for delivery of test results, such as PGx-information cards (43) provided to the 
patient and scannable Quick Response (QR) Codes (27) linked to a website with drug-
dosing recommendations tailored to a specific patient based on PGx-test results. Creating a 
national or international registry of patients who have undergone extensive PGx testing and 
are willing to share their PGx results and outcome information could be a low-cost and 
efficient means for studying rare ADEs and obtaining needed outcome data. Additional 
studies are needed to understand PGx-relevant variation and its clinical impact in 
underserved populations, such as non-European ancestry populations, children, and patients 
with limited access to care and financial capacity. Better methods are needed for identifying 
and studying outliers in drug response, as are systematic approaches to standardization of 
study outcomes, including patient-reported outcomes. Identifying additional genomic 
variants and genes influencing responses to commonly used drugs are still needed, and could 
capitalize on large-scale clinical trials of drug efficacy; it is recommended that such trials 
include collection of DNA from participants with appropriate consent for future PGx 
research.
Creation and testing of software applications or “plug-ins” for delivering information about 
gene-drug interactions and activation of CDS rules could build on models currently available 
for drug-drug interactions, but would need to support updating as new genomic variants are 
characterized. Research to enhance the role of community clinical pharmacists in PGx 
dissemination and implementation and to evaluate their effectiveness could shed light on this 
valuable and underutilized resource at the front line of patient interactions. Training and 
engaging this valuable community of providers in the development of CDS is essential. 
Engaging HIT personnel more directly in research or quality improvement would support 
more rapid implementation, not only of standardized terminology but also of more robust 
interfaces to transfer structured PGx test results and CDS rules. Ensuring such support and 
engagement of HIT experts will be critical to development of interoperable, potentially 
nationwide systems for PGx and other genomic data that could follow patients as they move 
across healthcare systems.
The Benefits of PGx Implementation
It is important to study whether PGx testing has direct patient-care benefits. Outcomes of 
interest would include decreasing common and rare ADRs, lowering the need for outpatient 
visits, reaching intended therapeutic effects faster or in a greater percentage of the 
population, and reducing the cost of care. Trial designs will be challenging, given that the 
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most severe ADEs and the most penetrant pharmacologically-relevant genomic variation are 
likely to be rare (15).
If costs of PGx testing continue to decline and reimbursement can be improved through 
more precise coding and evaluation of outcomes, demonstration of cost-effectiveness may 
become less of a barrier; however, it is important to measure other benefits, such as reduced 
need for outpatient visits or other monitoring. Clinicians and payers must also be educated 
on the falling costs of PGx tests and the efficiency of multigene panels, especially since 
panel-based PGx testing can cost as little as $150. Clinicians fearing liability for not acting 
upon PGx results as recommended by the American College of Medical Genetics and 
Genomics (ACMG) (44) should also be educated that comprehensive genome sequencing 
might reveal high-risk genomic variants for disease susceptibility or management for other 
conditions, and they might be liable whether they search for and report those results or not. 
Preemptive genotyping of patients likely to receive PGx-relevant drugs represents the most 
efficient method of PGx implementation and obviates the need for clinicians to initiate the 
testing.
In addition to physicians, multidisciplinary teams trained in PGx-based drug selection and 
dosing (including industry partners) can be very effective for improving and disseminating 
PGx experience. Partnerships among community-based practitioners, pharmacists, and 
genetic counselors – rather than reliance on a single health professional – will be needed for 
delivery of comprehensive PGx services (45), just as they are for the research to develop 
these services. The potential role of motivated patients in educating their clinicians should 
not be overlooked; providing educational resources to them will help in generating 
awareness that can then be transferred to clinicians by the patients themselves.
Evidence of benefits and risks of PGx testing is urgently needed, but generating such 
evidence through traditional randomized clinical trials could present serious ethical 
dilemmas for clinical investigators already convinced of the value of PGx testing. Many such 
researchers would have difficulty randomizing patients to receive a drug that the patient was 
known to be incapable of activating or at high risk of adverse effects. Some advocate instead 
for pragmatic clinical trials (46) or effectiveness-implementation hybrid designs trials (47). 
Recognizing that PGx quality-improvement projects cannot be implemented into all clinical 
systems at once, a phased roll-out could be considered where clinical sites are randomized as 
to when their implementation is begun, allowing sites randomized to late implementation to 
serve as controls for those randomized to early implementation. In addition, there may be 
other approaches, such as retrospective analyses and clinical simulations, that can provide 
platforms for generating evidence of benefits of PGx testing.
Conclusions
Implementation of PGx-guided drug selection and dosing presents many opportunities for 
improving drug safety, but its real-world clinical- and cost-effectiveness remains largely 
unproven. Such proof is needed to move PGx implementation from the vanguard of 
specialized, early-adopter centers to standard clinical care. The evidence base for PGx-
relevant genomic variants needs to expand to address many of the challenges highlighted 
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here, including analytical and clinical validity as well as clinical utility. As PGx knowledge 
and guidelines improve, along with innovative research designs and changes to healthcare 
delivery systems, sophisticated CDS systems and multidisciplinary education and 
collaboration will be needed to move clinical implementation of PGx from the exception to 
the norm of state-of-the-art patient care.
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Table 2
Summary of the pre-meeting PGx implementation survey (36 responding of 73 invited).
Question (N=total) Percent
Type of PGx Implementation (N=40)1 57 Clinical and Research
28 Clinical Only
15 Research Only
Responding Institution (36) 53 Academia
22 Non-academic setting
14 Hospital
11 Other healthcare setting
Triggers Prompting PGx Test Orders (N=40) 35 Reactive
65 Pre-emptive
Type of Alert Prompting PGx Test Order or Notification of PGx Test 
Results (N=39)
51 Active and Passive
31 Active (i.e. alert and/or specific message sent)
18 Passive (i.e. the test order was available on demand only)
Filing for 3rd Party Reimbursement for PGx Tests (N=37) 60
40
Filing
Not Filing
External Resources or Knowledgebases Used (N=36) 94 CPIC
78 PharmGKB
19 IGNITE Spark
17 ClinVar
Genotyping Platforms Used (N=47)* 38 Real-Time PCR Systems
17 DMET Panel
13 ADME Panel
32 Other
PGx Gene-Drug Pair Currently Tested (N=35) 91 CYP2C19-Clopidogrel
86 SLCO1B1-Simvastatin
83 CYP2C9/VKORC1-Warfarin
80 TPMT-Thiopurines
74 CYP2D6-Codeine
71 CYPG2C19 and/or CYP2D6-Antidepressants
60 DPYD-Fluorouracil, capecitabine
43 UGT1A1-Irinotecan, Belinostat, Nilotinib, Pazopanib, 
Erlotinib, Atazanavir, Abacavir, Indacaterol
40 IFNL3-Ribavarin, peginterferon
34 HLAB-Abacavir
31 HLA-Allopurinol, Carbamazepine, Phenytoin
1Some participants reported on more than one project.
2Some projects used more than one platform.
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